Article
Immunomodulating property of MAPK inhibitors: from translational knowledge to clinical implementation.
Laboratory investigation; a journal of technical methods and pathology - 1 Feb 2017
Mandalà Mario, De Logu Francesco, Merelli Barbara, Nassini Romina, Massi Daniela
Abstract excerpt
Treatment of metastatic melanoma was radically changed by the introduction of inhibitors of BRAF, an oncogene mutated in 40-50% of patients. Another area of advancement was the use of immunotherapy, and specifically, immune checkpoint inhibitors. There is compelling evidence that oncogenic BRAF, in addition to driving melanoma proliferation, differentiation and survival, induces T-cell suppression directly...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.